Last reviewed · How we verify

10% glucose solution

Umeå University · FDA-approved active Small molecule Quality 5/100

The 10% glucose solution, marketed by Umeå University, holds a position in the healthcare market as a widely recognized and utilized therapeutic agent. A key strength of this solution is its broad acceptance and established use, underpinned by a key composition patent that remains in effect until 2028. The primary risk to the product is the potential increase in competition once the key patent expires in 2028.

At a glance

Generic name10% glucose solution
SponsorUmeå University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: